Ligand Pharmaceuticals (LGND) Stock: Buy, Sell, or Hold?
LGND - Ligand Pharmaceuticals Inc.
$303.53
-4.29 (-1.39%)
âŧ
5d:
+2.7%
30d:
+1.5%
90d:
+2.03%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 29, 2026
4d
Get Alerted When LGND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LGND is fairly priced but lacks strong directional signals. At 3.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LGND is fairly priced but lacks strong directional signals. At 3.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$537.91
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$334.00
9.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LGND is currently trading at $303.53, which is considered fair relative to its 30-day fair value range of $288.28 to $308.95. The stock's valuation (Forward PE: 25.4) is in line with its historical norms (23.1). At these levels, the market is pricing in 3.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LGND is in a uptrend. Immediate support is located at $292.28, while resistance sits at $317.64.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $345.75 (+13.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LGND is in a uptrend. Immediate support is located at $292.28, while resistance sits at $317.64.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $345.75 (+13.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$288.28 -
$308.95
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
76.5%
Protect Your Profits
Holding LGND? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($345.75)
- NEUTRAL: Market pricing in 3.2% annual earnings growth - fairly valued
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$288.28 -
$308.95
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$17.23
(5.7%)
Support & Resistance Levels
Support Level
$292.28
Resistance Level
$317.64
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
25.38
Wall Street Target
$345.75
(+13.9%)
Revenue Growth (YoY)
33.7%
Earnings Growth (YoY)
825.0%
Profit Margin
67.9%
Valuation Premium vs History
+3.2% premium
PE vs Historical
25.4 vs 23.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.2%
(market-implied from PE analysis)
1-Year Target
$313.24
(+3%)
2-Year Target
$323.27
(+7%)
3-Year Target
$333.61
(+10%)
3-Yr Target (if PE normalizes)
(PE: 25â23)
PE COMPRESSION
$303.60
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 25.4, Growth: 27.9%)
$635.64
(+109%)
Base:
(SPY PE: 19.9, Growth: 27.9%)
$497.32
(+64%)
Bear:
(PE: 16.9, Growth: 27.9%)
$422.72
(+39%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 32.44 | Current EPS (TTM): $9.49
Bull Case
$426.65
(+41%)
Analyst growth 26.0%, PE expands to 35.7
Base Case
$387.87
(+28%)
Market implied 26.0%, PE stable at 32.4
Bear Case
$209.32
(-31%)
Severe decline -20.0%, PE contracts to 27.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 9:54 PM ET
Data refreshes hourly during market hours. Next update: 10:54 PM
Data refreshes hourly during market hours. Next update: 10:54 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LGND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 53 HOLD |
Advanced LGND Option Strategies
Professional options setups generated by AI based on today's LGND price and gamma walls.
